Rogel Cancer Center: University of Michigan
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2010-11-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00156286
- Locations
- 🇺🇸
Univeristy of Michigan Cancer Center, Ann Arbor, Michigan, United States
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00156273
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00156312
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT00156260
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
- Conditions
- Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00161278
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Procedure: tissue procurement
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT00161265
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00151047
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00151060
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer, Ann Arbor, Michigan, United States
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
- Conditions
- Urologic Neoplasms
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00151034
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸California City of Hope National Medical Group, Duarte, California, United States
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
- Conditions
- Hormone-Refractory Prostate Cancer
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00151073
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States